Clinical trial
A Phase 2, 2-panel, Open-label Randomized Study in Hepatitis C Virus Infected Subjects to Investigate the Pharmacokinetic Interactions Between Simeprevir and Ledipasvir in a Treatment Regimen Consisting of Simeprevir, Sofosbuvir and Ledipasvir in Treatment-naive Participants.
NCT02421211 is registered in ClinicalTrials.gov with Janssen Sciences Ireland UC as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2, 2-panel, Open-label Randomized Study in Hepatitis C Virus Infected Subjects to Investigate the Pharmacokinetic Interactions Between Simeprevir and Ledipasvir in a Treatment Regimen Consisting of Simeprevir, Sofosbuvir and Ledipasvir in Treatment-naive Participants.
- Lead sponsor
- Janssen Sciences Ireland UC
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- May 19, 2015
- Completion date
- January 27, 2016
- Enrollment
- 41 (actual)
- Sites
- 4
Conditions
As the registry lists them; a condition with its own page is linked.